[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chinese University of Hong Kong\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":575},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,395,0,25,[9,45,70,97,120,141,162,189,212,231,254,272,289,307,335,360,380,400,420,441,460,484,508,530,557],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100622961","duodenal-pulsendo-for-suboptimally-controlled-type-ii-diabetes-mellitus-and-steatotic-liver-disease-100622961",false,"NCT07390422","Duodenal pulsENDO for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease","Duodenal Recellularization Via Electroporation Therapy for Suboptimally Controlled Type II Diabetes Mellitus and Steatotic Liver Disease (DRESS-1 Study)","DRESS-1","Inclusion Criteria:\n\n* Duration of T2DM \\\u003C 10 years\n* BMI 18.5-40kg\u002Fm2\n* Failure to achieve adequate HbA1c reduction (7.5 - 11%) after at least 3 months stable dosage of oral glucose lowering drugs\n\nExclusion Criteria:\n\n* Previous treatment with pulsENDO or similar procedure\n* Previous GI surgery that could preclude the ability to perform pulsENDO, or acute gastric and duodenal pathology that increased the risk of pulsENDO\n* Type 1 DM, DM secondary to specific disease or having any history of ketoacidosis\n* Patients on insulin\n* Fasting C-peptide level \\\u003C0.5ug\u002FL\n* Any inflammatory disease of the gastrointestinal tract such as Crohn's disease\n* Abnormal pathologies or conditions of the gastrointestinal tract, including duodenal polyps, ulcers or upper gastrointestinal bleeding conditions within 3 months of study\n* Uncorrectable bleeding diathesis, platelet dysfunction, thrombocytopenia with platelet count less than 100,000\u002Fmicroliter or known coagulopathy\n* Currently taking prescription antithrombotic therapy (e.g., anticoagulant or antiplatelet agent) within 10 days prior to study and\u002For there is a need or expected need to use during the study period\n* Currently taking medications known to cause significant weight gain or weight loss (e.g. chemotherapeutics)\n* Patients who have used non-steroidal analgesics and anti-inflammatory drugs (NSAID) and corticosteroids in the past 1 month\n* Underlying uncontrolled endocrine problem that leads to obesity, including and not limited to hypothyroidism, Cushing syndrome and eating disorder.\n* Patients with contra-indications to endoscopy\n* Patients with cirrhosis due to causes other than MASLD\n* Malignancy\n* Diagnosis of autoimmune connective tissue disorder (e.g. lupus erythematosus, scleroderma)\n* Pregnant or breast feeding\n* ASA grade IV \\& V\n* Mental or psychiatric disorder; Drug or alcohol addiction\n* Other cases deemed by the examining physician as unsuitable for safe treatment\n* Refusal to participate","ALL","18 Years","70 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is designed to evaluate the efficacy, safety, and mechanisms of pulsENDO procedure in patients with T2DM and its effect on MASLD.",[29,30,31],"T2DM (Type 2 Diabetes Mellitus)","MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Syndrome (MetS)","NOT_YET_RECRUITING","2026-08-17",{"date":35,"type":36},"2026-08-18","ACTUAL",{"date":38,"type":23},"2026-09-01",{"date":40,"type":23},"2033-08-30",{"name":42,"class":43},"Chinese University of Hong Kong","OTHER",1,{"id":46,"slug":47,"hasResults":12,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":24,"phases":54,"briefSummary":55,"conditions":56,"keywords":59,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":44},"100652233","cognitive-behavioral-therapy-for-insomnia-as-an-adjunct-to-time-restricted-eating-on-weight-loss-in-adults-with-overweight-or-obesity-and-chronic-insomnia-100652233","NCT07770516","Cognitive Behavioral Therapy for Insomnia as an Adjunct to Time-restricted Eating on Weight Loss in Adults With Overweight or Obesity and Chronic Insomnia","Effects of Cognitive Behavioral Therapy for Insomnia (CBTI) as an Adjunct Intervention for Time-restricted Eating on Weight Loss in Adults With Overweight or Obesity and Chronic Insomnia","Inclusion Criteria:\n\n1. Ethnic Chinese;\n2. Age 18 years or older;\n3. Fulfill the criteria of chronic insomnia defined by Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) , which are:\n\n   i. manifestation of predominant, subpar sleep quantity or quality; ii. exhibition of any sleep difficulties ranging from sleep initiation, sleep maintenance to early awakening with the inability to restore sleep.\n\n   iii. concomitant presentation of significant distress or impairment, including fatigue or low energy, cognitive impairment, mood disturbance, behavioral problems, impaired occupational or academic functioning, impaired interpersonal or social functioning and negative impact on caregiver or family functioning; iv. sleep difficulty occurs at least three nights per week; v. sleep difficulty has been persistent for at least three months; and vi. sleep difficulty is not affected regardless of adequate opportunity given for sleep.\n4. With Overweight or obesity: BMI ≥ 23 kg\u002Fm2\n5. Weight stable for the past 3 months\n6. Habitual eating window ≥ 10 hours\n\nExclusion Criteria:\n\n1. Known cardiovascular disease;\n2. Type 1 or 2 diabetes mellitus;\n3. Current use of GLP-1 receptor agonists or other prescription weight-loss medications within the past 3 months;\n4. Currently on a special or prescribed diet for other reasons;\n5. Currently receiving any psychological treatment for insomnia;\n6. Previously received CBTI;\n7. Night shift workers;\n8. Breastfeeding, pregnant or trying to become pregnant;\n9. Smokers.",{"count":53,"type":23},50,[26],"Obesity (being overweight due to excess body fat) is a common health condition that increases the risk of developing problems such as diabetes, high blood pressure, and heart disease. Time-restricted eating (TRE), which involves eating all meals within a set period each day, has become a popular and simple approach for weight management. However, not everyone achieves the same results from TRE. Research suggests that poor sleep and chronic insomnia can increase hunger, affect food choices, and lead to higher calorie intake, which may make weight loss more difficult.\n\nThis study aims to examine whether improving sleep can enhance the effectiveness of flexible time-restricted eating (FTRE) for weight loss. Participants will receive either FTRE alone or FTRE combined with Cognitive Behavioural Therapy for Insomnia (CBTI), a well-established treatment for chronic insomnia. By comparing these two approaches, this study will help determine whether addressing sleep problems can improve weight management outcomes in individuals with overweight or obesity and chronic insomnia. The findings may contribute to the development of more effective and comprehensive lifestyle programmes for improving both sleep and weight-related health.",[57,58],"Chronic Insomnia","Overweight\u002FObesity",[60,61,62],"Chronic insomnia","Time-restricted eating","Cognitive Behavioural Therapy of Insomnia","2026-08-14",{"date":35,"type":36},{"date":66,"type":23},"2026-08-25",{"date":68,"type":23},"2027-06-30",{"name":42,"class":43},{"id":71,"slug":72,"hasResults":12,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":24,"phases":80,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":92,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":44},"100652077","integrating-ai-assisted-design-thinking-into-nursing-education-100652077","NCT07767292","Integrating AI-Assisted Design Thinking Into Nursing Education","Integrating Design Thinking Into Undergraduate Nursing Education to Nurture Empathy and Enhance Empathetic Communication: a Wait List RCT","Inclusion Criteria:\n\n* Undergraduate nursing students enrolled in the Bachelor of Nursing programme at CUHK Nethersole School of Nursing.\n* Enrolled in the NURS 3127 course during the 2026-27 academic year.\n* Willing and able to provide verbal informed consent and participate voluntarily in the study.\n\nExclusion Criteria:\n\n* Students with prior participation in design-thinking workshops.",true,{"count":79,"type":23},80,[26],"The goal of this randomized controlled trial is to test whether an AI-assisted design thinking workshop can improve empathetic communication in undergraduate nursing students at The Chinese University of Hong Kong. The main questions it aims to answer are:\n\nDoes the workshop improve students' empathy, creativity, collaboration, problem-solving, and patient-centred care attitudes?\n\nHow do students experience the design thinking and AI-supported learning activities?\n\nResearchers will compare the intervention group with a wait-list control group to see whether the workshop leads to better outcomes.\n\nParticipants will:\n\ncomplete a baseline questionnaire before the workshop;\n\nbe randomly assigned to receive the workshop now or later;\n\nattend two tutorials in the intervention group, including design thinking activities and AI-simulated clinical scenarios;\n\ncomplete a follow-up questionnaire after the workshop;\n\nand, for some participants, join a short interview about their learning experience.",[83],"Nurse Training",[85,86,87,88,89,90,91],"Design thinking","Nursing education","Problem- solving skills","Empathy","Creativity","Patient-centered care attitude","Collabration",{"date":33,"type":36},{"date":66,"type":23},{"date":95,"type":23},"2027-08-24",{"name":42,"class":43},{"id":98,"slug":99,"hasResults":12,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":24,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":44},"100551793","to-investigate-the-effect-of-pemf-for-pateitns-after-anterior-cruciate-ligament-reconstruction-with-hamstring-autograft-100551793","NCT06464705","To Investigate the Effect of PEMF for Pateitns After Anterior Cruciate Ligament Reconstruction With Hamstring Autograft","Effect of Pulsed Electromagnetic Fields on Promoting Hamstring Muscle Strength After Anterior Cruciate Ligament Reconstruction With Hamstring Autograft: A Double-Blind, Placebo-Controlled, Randomised Clinical Trial","Inclusion Criteria:\n\n1. Male and female with age ≥ 18 years at the time of surgery\n2. First ACLR with HT autograft\n3. Both knees without a history of injury\u002Fprior surgery\n4. LSI for hamstring strength \\\u003C85% of contralateral leg at 4-month isokinetic assessment (70)\n5. Voluntarily agreed to participate and signed the informed consent form\n\nExclusion Criteria:\n\n1. Any concomitant bone fracture, major meniscus injury or full-thickness chondral injuries requiring altered rehabilitation program post-op\n2. Preoperative radiographic signs of arthritis\n3. Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)\n4. Patient with a pacemaker, an implantable defibrillator, neurosurgical clips, a neurostimulator, cochlear implant, a stent, an insulin pump\n5. Pregnant or breastfeeding\n6. Inability to give informed consent",{"count":105,"type":23},60,[26],"Anterior cruciate ligament (ACL) tear is common. It accounts for over 50% of all knee injuries. Anterior cruciate ligament reconstruction (ACLR) with hamstring tendon (HT) autograft is the common graft choice for ACLR. However, the outcomes of donor site healing and recovery of muscle strength of HT are not satisfactory, resulting in hamstring muscle weakness and hamstring strength deficit during deep knee flexion, which may lead to hamstring strain after ACLR. Moreover, activation of the hamstring muscle is vital for maintaining dynamic knee joint stability and preventing excessive ACL shear forces. The presence of hamstring muscle deficits after surgery therefore affects the function of the reconstruction ACL. A previous study has reported that the hamstring muscle showed nearly 20% strength deficit at 4 months after ACLR with hamstring autograft\n\nPulsed electromagnetic field (PEMF) treatment is a non-invasive therapy that has been shown to enhance muscle cell activity and accelerate tissue repair. In clinic, PEMF treatment has been reported to be safe.\n\nThis study aims to conduct a double-blinded, placebo-controlled randomised clinical trial to investigate the effects of PEMF therapy for improving the tissue regeneration and strength of the HT donor site in ACLR patients with HT autograft.",[109,110],"Anterior Cruciate Ligament Reconstruction","Hamstring Muscle","RECRUITING","2026-08-10",{"date":114,"type":36},"2026-08-12",{"date":116,"type":36},"2024-06-13",{"date":118,"type":23},"2027-03-31",{"name":42,"class":43},{"id":121,"slug":122,"hasResults":12,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":127,"targetDuration":4,"studyType":24,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":44},"100484131","a-single-blind-rct-to-investigate-the-effect-of-a-novel-herbal-patch-for-the-treatment-of-pf-100484131","NCT05584046","A Double-blind RCT to Investigate the Effect of a Novel Herbal Patch for the Treatment of PF","Effect of a Novel Herbal Patch for the Treatment of Plantar Fasciitis - A SingleDouble-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Male and female with age 18-70\n* Unilateral\n* Heel pain for more than 6 weeks' duration\n* VAS score ≥ 5\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Known chronic disease or receiving long-term medications affecting bone metabolism including BPs\n* Contraindication to alendronate therapy such as poor dental fitness\n* ACL injury less than 6 weeks\n* Injury on duty cases\n* Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months\n* Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)\n* Chondral lesion with concomitant intervention\n* Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts\n* Neurological deficit\n* Pregnant or breastfeeding\n* Inability to give informed consent",{"count":128,"type":23},120,[26],"Disorders and injuries of tendons and ligaments are some of the most diagnosed musculoskeletal (MS) disorders clinically. Nearly half of the 33 million MS disorders reported in the United States each year are tendon and ligament injuries. Although most of such injuries are non-fatal, they are severely debilitating, resulting in significant reduction in patient's quality of life, loss of productivity, and considerable costs to the healthcare system.\n\nAmong all tendon and ligament disorders and injuries, tendon and ligament overuse disorders are the most common and incapacitating ones. Tendinopathy is a painful tendon overuse disorder, which increases with population aging. It has been estimated that about 30% of consultations for MS complaints in a general practice were related to tendinopathy. The affected tendon is presented with local tenderness, swelling and pain, causing physical disability of the affected individual. The affected tendon degenerates and finally ruptures. Common sites of tendinopathy include supraspinatus, common wrist extensor, flexor tendon, patellar tendon, and Achilles tendon. The outcomes of both conservative treatments and surgeries are not satisfactory, with recurrent pain and tendon retear after surgery.\n\nPlantar fasciitis is a chronic painful, degenerative condition of the plantar fascia. It is caused by repetitive traumas at its origin on the calcaneus. Plantar fascia is a thick, ribbon-like fibrous ligament that connects the medial calcaneal tubercle to the heads of the metatarsal bones. It contributes to the support of the foot arch by acting as a tie-rod, where it undergoes tension when the foot bears weight. Therefore, although plantar fascia is anatomically defined as a ligament, it functions similar to a tendon.\n\nThis study aims to conduct a randomized controlled study to test the efficacy of CDAM patch for the treatment of plantar fasciitis in patients.",[132],"Plantar Fasciitis",[132,134],"Herbal Patch",{"date":114,"type":36},{"date":137,"type":36},"2023-09-20",{"date":139,"type":23},"2028-12-31",{"name":42,"class":43},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":12,"sex":18,"minAge":148,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":24,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":44},"100479789","phase-4-a-single-blind-rct-to-investigate-the-effect-of-alendronate-on-knee-function-following-aclr-100479789","NCT05527548","A Multi-centre, Double-blind RCT to Investigate the Effect of Alendronate on Knee Function Following ACLR","The Effect of Oral Administration of Alendronate on Knee Functions Following Anterior Cruciate Ligament Reconstruction - A Multi-Centre, Double-Blind, Placebo-Controlled, Randomized Trial","Inclusion Criteria:\n\n* Male and female with age 14 or above at the time of surgery\n* First ACLR\n* Single leg involvement\n* Able to attend pre-operative assessment\n* Voluntarily agreed to participate and signed the informed consent form\n\nExclusion Criteria:\n\n* Known chronic disease or receiving long-term medications affecting bone metabolism including BPs\n* Contraindication to alendronate therapy such as poor dental fitness\n* ACL injury less than 6 weeks\n* Injury on duty cases\n* Patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months\n* Other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury)\n* Chondral lesion with concomitant intervention\n* Presence of X-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts\n* Neurological deficit\n* Pregnant or breastfeeding\n* Inability to give informed consent","14 Years",{"count":150,"type":23},100,[152],"PHASE4","Anterior cruciate ligament (ACL) is the key ligament connecting the femur to tibia that helps stabilising the knee joint. ACL tear is common. It accounts for over 50% of all knee injuries and affects more than 200,000 people in the United States each year. Patients with ACL tear have a higher risk of developing post-traumatic osteoarthritis. ACL reconstruction (ACLR) with the attachment of tendon grafts within bone tunnels are commonly performed to restore the stability of the joint and thereby minimise injury to both the chondral surface and surrounding tissues. About 130,000 ACLR was performed in the United States in 2006. Both the incidence rates of ACL injuries and ACLR are on the rise, particularly in children and adolescents. Conventional ACLR is not a universally successful procedure, with long healing time and high rates of graft failure (2.8%) and graft laxity (18%). The average cost of an ACLR in the United States was about USD 24,707 ±15,644. The cost for revision surgery and societal cost due to absence from work and sport are expected to be even higher. The demand for a better intervention to improve the outcomes after ACLR and reduce the healing time is huge.\n\nALN was chosen for the pilot study because it is the most studied BPs, with high bone-binding affinity and more prolonged duration of action. As a member of amino BPs, it also has higher anti-resorptive activities compared to non-amino BPs. Our encouraging results on ALN in the animal studies also provide evidence to support the trial of ALN in human.\n\nALN have been shown to have a very good safety and tolerability profile. The common side effects of ALN are stomach pain, constipation, diarrhoea, gas, or nausea. Oral ALN seems can induce mild gastro-intestinal disturbances. However, two studies, with subjects treated with ALN for 10 months and 2.9 years, respectively, showed that ALN was not associated with any increased incidence of upper GI tract events. The serious adverse event, oesophageal cancer, has been associated with ALN. However, two published papers with long term observations of 9 and 4.5 years, respectively, showed that ALN was not significantly associated with incident oesophageal or gastric cancer compared with the control group.\n\nThis study aims to evaluate the effects of oral administration of ALN on knee stability (primary), peri-tunnel bone loss, tunnel bone formation, knee laxity, knee muscle strength as well as self-reported knee symptoms, function and sports activity over 12 months in patients undergoing ACLR in a pilot study of single-blind randomised controlled trial.",[155],"ACL Reconstruction",{"date":114,"type":36},{"date":158,"type":36},"2022-12-22",{"date":160,"type":23},"2028-07-22",{"name":42,"class":43},{"id":163,"slug":164,"hasResults":12,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":77,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},"100651012","comprehensive-clinical-prediction-rule-for-acute-heart-failure-100651012","NCT07754084","Comprehensive Clinical Prediction Rule for Acute Heart Failure","Establishing a Comprehensive Clinical Prediction Rule for the Diagnosis of Acute Heart Failure in the Emergency Department","Inclusion Criteria:\n\n* Adult (aged ≥ 18 years)\n* Suspected AHF or acute dyspnea\n* Symptoms include shortness of breath, swelling of legs, orthopnea, paroxysmal nocturnal dyspnoea, exertional dyspnea or weight gain\n\nExclusion Criteria:\n\n* Trauma patients\n* Pregnancy\n* Unstable patients requiring invasive airway intervention\n* Patients who refuse to participate",{"count":170,"type":23},560,"OBSERVATIONAL","The goal of this prospective observational cohort study is to establish a comprehensive clinical prediction rule integrating clinical characteristics, point-of-care testing (POCT) of NT-proBNP, an 8-point LUS, and a rapid cardiac assessment using bedside echocardiography for diagnosing acute heart failure (AHF) in the emergency department. A clinical prediction rule with high diagnostic accuracy will minimize delays and misdiagnoses, as well as the potential harm they may cause to patients. The primary outcome measure is the adjudicated AHF diagnosis. Secondary outcome measures include ED and discharge diagnosis of the patients.",[174],"Acute Heart Failure (AHF)",[176,177,178,179,180],"Acute Heart Failure","LUS","CXR","ECG","NT-proBNP","2026-08-09",{"date":183,"type":36},"2026-08-11",{"date":33,"type":23},{"date":186,"type":23},"2029-01-31",{"name":42,"class":43},3,{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":196,"minAge":197,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":200,"conditions":201,"keywords":203,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":207,"completionDateStruct":208,"leadSponsor":210,"locationsCount":211},"100651518","investigation-of-an-intelligent-centre-adaptive-multi-modal-fusion-framework-cad--mmff-to-overcome-unnecessary-prostate-biopsies-and-optimize-mri-utilization-100651518","NCT07760857","Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization","Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization: a Hybrid Retrospective-prospective Study","Inclusion Criteria:\n\n* Ethnically Chinese men aged ≥ 50\n* Suspicion of PCa \\[elevated PSA (\\>4-ng\u002Fml) or abnormal DRE\u002FPHI\\] and indicated for prostate biopsy\n* Obtained clinical consent (for prospectively enrolled patients only)\n\nExclusion Criteria:\n\n* Prior biopsy\u002Ftreatments for PCa\n* History of genitourinary cancer\n* Poor image quality\n* Incomplete imaging scans\u002Fclinical data\u002Fpathological results","MALE","45 Years",{"count":199,"type":23},400,"This study aims to investigate a novel Centre-Adaptive Multi-Modal Fusion Framework (Cad-MMFF) that integrates clinical, ultrasound, and MRI data to improve the detection of clinically significant prostate cancer (csPCa), reduce unnecessary biopsies, and optimize MRI utilization.",[202],"Prostate Cancer (Diagnosis)",[204],"Modelling","2026-08-07",{"date":114,"type":36},{"date":38,"type":23},{"date":209,"type":23},"2030-03-31",{"name":42,"class":43},2,{"id":213,"slug":214,"hasResults":12,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":230,"locationsCount":211},"100643486","aortic-dissection-detection-risk-score-with-d-dimer-to-rule-out-acute-aortic-syndrome-100643486","NCT07640334","Aortic Dissection Detection Risk Score With D-dimer to Rule-Out Acute Aortic Syndrome","The Combination of Aortic Dissection Detection Risk Score With D-dimer to Rule-Out Acute Aortic Syndrome: Multicentre Prospective Study in Emergency Departments","Inclusion Criteria:\n\n* Adult patients aged ≥ 18 years; AND\n* Presentation to the ED with any of the following symptoms: acute onset (\\\u003C14 days) chest pain, abdominal pain, back pain, syncope, or signs of malperfusion (e.g. limb ischemia, neurological deficit); AND\n* AAS is considered as a possible differential diagnosis by the treating physician. Enrolment in the study will be determined by the attending physician during initial medical consultation in the ED and prior to establishing a final diagnosis.\n\nExclusion Criteria:\n\n* An alternative diagnosis to AAS established by the treating physician after the initial assessment; OR\n* Trauma cases; OR\n* Patients with a known diagnosis of AAS before the index ED visit (e.g. with a diagnostic imaging done before the ED visit or referral from other institutions for AAS); OR\n* Clinical severity or other conditions not allowing complete evaluation\u002Fproper enrolment; OR\n* Patient who refuse to participate.",{"count":220,"type":23},746,"The goal of this study is to evaluate the safety of integrating the Aortic Dissection Detection Risk Score (ADD-RS) and D-dimer testing for ruling out acute aortic syndrome (AAS) in the emergency department (ED). The main question it aims to answer: Can the combination of the ADD-RS \\\u003C2, and D dimer \\\u003C500ng\u002FmL rule-out AAS in ED patients without CTA? The researchers will recruit patients suspected with AAS in the ED, and the patients will receive a ADD-RS score, a D-dimer testing after signing a written consent.",[223],"Acute Aortic Syndrome","2026-08-03",{"date":226,"type":36},"2026-08-05",{"date":228,"type":23},"2026-07-13",{"date":139,"type":23},{"name":42,"class":43},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":196,"minAge":238,"maxAge":20,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":245,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":44},"100648904","evaluation-of-the-aulea-veloxion-disposable-resectoscope-system-for-operational-efficiency-in-surgical-management-of-benign-prostatic-hyperplasia-bph-100648904","NCT07728071","Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)","Prospective, Single-Site, Single-Arm Evaluation of the Aulea Veloxion™ Disposable Resectoscope System for Operational Efficiency in Surgical Management of Benign Prostatic Hyperplasia (BPH)","Inclusion Criteria:\n\n* Age 30-70 years old with symptomatic BPH.\n* Prostate volume 20-120 mL (TRUS\u002FMRI\u002FUS)\n* Suitable for endoscopic resection\u002Fvaporization per device IFU.\n* Able to consent and comply with follow-up to 1 month.\n\nExclusion Criteria:\n\n* Known\u002Fsuspected prostate cancer requiring oncologic management.\n* Prior prostate surgery impacting urethral anatomy within 12 months.\n* Prior implant affecting urethral anatomy.\n* Active UTI or untreated bacteriuria pre-op.\n* Uncorrectable coagulopathy; inability to manage antithrombotics.\n* Severe medical comorbidity precluding anesthesia or endoscopy.","30 Years",{"count":240,"type":23},20,[26],"Prospective, single-arm, single-site, post-market device study; all procedures use Veloxion™ per IFU.",[244],"BPH (Benign Prostatic Hyperplasia)",[246],"Surgical management of BPH","2026-07-31",{"date":224,"type":36},{"date":250,"type":23},"2026-07-16",{"date":252,"type":23},"2027-12-31",{"name":42,"class":43},{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":24,"phases":263,"briefSummary":264,"conditions":265,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":267,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":271,"locationsCount":211},"100648648","role-of-erbt-plus-intravesical-bcg-in-intermediate-risk-or-high-risk-nmbc-100648648","NCT07724886","Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC","A Randomised Trial Investigating the Role of Transurethral En Bloc Resection of Bladder Tumour Plus Intravesical Bacillus Calmette-Guerin Therapy, in Patients With Intermediate-Risk or High-Risk Non-Muscle-Invasive Bladder Cancer","Inclusion Criteria:\n\n* Age 18 years or above\n* Fulfil any one of the following three criteria:\n\n  1. Recurrent bladder tumour\n  2. Multiple bladder tumours\n  3. Any bladder tumour size of \\>1cm\n\nExclusion Criteria:\n\n* EAU low-risk NIMBC as intravesical BCG therapy should not be offered (5)\n* EAU very high-risk NMIBC as upfront radical cystectomy should be offered (5)\n* Any prior use of intravesical BCG therapy\n* Presence or prior history of upper urinary tract malignancy\n* Presence of clinically significant cardiovascular disease (History of acute myocardial infarction, presence of uncontrolled angina within 3 months before screening, New York Heart Association Class III or IV congestive heart failure, presence of ventricular arrhythmias, or presence of second-degree or third-degree heart block) (16)\n* Presence of GOLD Stage III or IV chronic obstructive pulmonary disease\n* ECOG performance status ≥ 2 (Ambulatory and capable of all self-care but unable to carry our any work activities) (18)\n* History of bleeding disorder or use of anti-coagulants\n* Pregnancy\n* Presence of other active malignancy",{"count":262,"type":23},732,[26],"This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.",[266],"Bladder Cancer",{"date":224,"type":36},{"date":269,"type":23},"2026-07-01",{"date":209,"type":23},{"name":42,"class":43},{"id":273,"slug":274,"hasResults":12,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":283,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":44},"100472949","a-comprehensive-prospective-assessment-of-the-physical-and-biological-effects-of-upper-tract-urothelial-cancer-utuc-100472949","NCT05438537","A Comprehensive Prospective Assessment of the Physical and Biological Effects of Upper Tract Urothelial Cancer (UTUC)","Inclusion Criteria:\n\n* Male patients \\> 18 years old\n* Patients who has presence of UTUC and pending for surgery\n* Patients who has history of UTUC with any intervention performed\n\nExclusion Criteria:\n\n\\- Patients fail to provide informed consent",{"count":279,"type":23},300,"There are many controversies and limitations in the management of Upper Tract Urothelial cancer. A prospective registry is set up for patients in our hospital, aim to have a comprehensive prospective assessment of the physical and biological effects of Upper Tract Urothelial cancer in our patients",[282],"Upper Tract Urothelial Cancer",{"date":224,"type":36},{"date":285,"type":36},"2021-11-01",{"date":287,"type":23},"2030-12-30",{"name":42,"class":43},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":295,"targetDuration":297,"studyType":171,"phases":4,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":302,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":306,"locationsCount":211},"100434239","the-global-en-bloc-resection-of-bladder-tumour-registry-100434239","NCT04934540","The Global En Bloc Resection of Bladder Tumour Registry","Inclusion Criteria:\n\n* Adult patients \\>=18 years old with informed consent\n* Presence of bladder tumour undergoing transurethral ERBT\n\nExclusion Criteria:\n\n* Presence or previous history of upper tract urothelial carcinoma\n* Presence of other active malignancy\n* Pregnancy",{"count":296,"type":23},2000,"5 Years","The study aims to collect data on ERBT globally in order to clarify its role in the management of bladder cancer over a 5-year observation period.",[266],[301],"En bloc resection of bladder tumour",{"date":224,"type":36},{"date":304,"type":36},"2020-01-01",{"date":252,"type":23},{"name":42,"class":43},{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":313,"eligibilityCriteria":314,"healthyVolunteers":77,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":24,"phases":317,"briefSummary":318,"conditions":319,"keywords":323,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":332,"leadSponsor":334,"locationsCount":4},"100649493","evaluation-of-a-couple-based-psycho-socio-educational-intervention-using-wechatwhatsapp-on-dyadic-psychological-and-sleep-outcomes-100649493","NCT07736378","Evaluation of a Couple-based Psycho-socio-educational Intervention Using WeChat\u002FWhatsApp on Dyadic Psychological and Sleep Outcomes","Evaluation of a Couple-based Psycho-socio-educational Intervention Using WeChat\u002FWhatsApp on Dyadic Psychological and Sleep Outcomes: A 3-armed Randomised Controlled Trial","WeLove RCT","Inclusion:\n\n* pregnant women over the age of 18\n* pregnant women's partners over the age of 18\n* women with a gestation of 12 to 28 weeks\n* women and their partners can read and understand Chinese\n* women and their partners possess electronic devices equipped with WhatsApp or WeChat\n* women and their partners can provide written informed consent.\n\nExclusion:\n\n* pregnant women and\u002For partners with current severe medical illnesses\n* women and\u002For their partners with psychological problems\n* women and\u002For their partners with sleep disorders",{"count":316,"type":23},336,[26],"Background: Pregnancy is a challenging time, and couples frequently experience psychological and sleep problems. Despite the dyadic effects of these problems, most interventions have focused on pregnant women alone, not on couples. The research team developed an innovative intervention targeting couples during pregnancy to fill the research gaps.\n\nObjectives: (1) examine the effects of couple-based psycho-socio-educational intervention using WeChat\u002FWhatsApp (WeLove) on dyadic psychological symptoms (depression, anxiety, stress symptoms), sleep quality, and life satisfaction with wearable data (stress, heart rate, and sleep quality) immediately after the intervention, with follow-up assessments at 3 months and 12 months after the intervention; and (2) examine the interdependence between psychological symptoms and sleep quality in pregnant women and their partners.\n\nMethods: WeLove is a 6-week online intervention through WeChat\u002FWhatsApp based on theoretical and evidence-based support. A three-arm double-blind randomized controlled trial will be used among 336 couples. Participants will be assigned to one of three groups and 112 couples per group: intervention 1 (couples for WeLove), intervention 2 (pregnant women for WeLove), or the control group (use WeChat\u002FWhatsApp as normal). Participants will be assessed pre- and post-intervention, with follow-up assessments at 3 months and 12 months after the intervention. Generalized estimating equation analysis and thematic analysis will be performed to examine the research objectives.\n\nPotential contributions: The findings will provide a cost-effective way to improve psychological and sleep outcomes in couples. Policymakers can use the study's results as evidence to consider an innovative intervention that aims to improve antenatal services in Hong Kong.",[320,321,322],"Sleep Problems","Psychological","Well-Being, Psychological",[324,325,326,327],"Couple-based intervention","Psycho-socio-educational intervention (WeLove)","Psychological well-being","Sleep outcome","2026-07-29",{"date":330,"type":36},"2026-07-30",{"date":250,"type":23},{"date":333,"type":23},"2030-07-14",{"name":42,"class":43},{"id":336,"slug":337,"hasResults":12,"nctId":338,"briefTitle":339,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":342,"targetDuration":4,"studyType":24,"phases":344,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":357,"leadSponsor":359,"locationsCount":44},"100649911","phase-2-study-of-robotic-assistedimage-guided-electromagnetic-navigation-bronchoscopic-therapies-and-surgery-in-stage-ia-nsclc-100649911","NCT07741344","Study of Robotic Assisted\u002FImage Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC","A Dual-Phase Study Comparing Survival, Immune Activation, and Functional Preservation Between Robotic-assisted \u002F Image Guided Electromagnetic Navigation Bronchoscopic Therapies and Surgery in Stage IA NSCLC","Bronchoscopic Microwave Ablation Group Inclusion Criteria\n\n1. Adults aged ≥18 years\n2. Histologically or cytologically confirmed stage IA NSCLC (T1N0M0, tumor ≤3 cm)\n3. Determined by multidisciplinary evaluation to be an appropriate candidate for bronchoscopic ablation as part of standard clinical care, and the patient agrees to a lung-preserving treatment approach\n4. Tumour size less than 2.5 cm in maximum diameter as measured on thin-slice chest CT\n5. Tumour located in the middle or peripheral third of the lung parenchyma\n6. Imaging and clinical evaluation indicate no lymph node involvement, and lymph node dissection for staging is not required\n7. Medically fit for bronchoscopic procedure under standard institutional anaesthesia protocols\n8. Pulmonary function results or clinical assessment indicate significant benefit from preserving lung tissue, such as predicted FEV1 or DLCO less than 40%, or clinician judgment that lung preservation is critical for quality of life\n9. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n\nExclusion Criteria\n\n1. Presence of lymph node involvement (N1 or higher) or distant metastases (M1)\n2. Centrally located tumours within the inner third of the lung or those requiring ablation near major airways\n3. Tumours adjacent to heat-sensitive structures (e.g., main bronchi, oesophagus, pericardium, aorta, or pulmonary artery) where adequate ablation margins cannot be safely achieved\n4. Rapidly enlarging lesions or those with high metabolic activity on PET-CT that warrant surgical resection and lymph node evaluation\n5. Imaging findings suggesting possible nodal involvement that necessitate surgical dissection for accurate staging\n6. Pregnant or breastfeeding women\n7. Inability or unwillingness to comply with study procedures\n8. Presence of electronic implants (e.g., pacemaker or defibrillator) at risk of interference from microwave energy\n9. Active pulmonary infection, uncorrectable coagulopathy, or ASA score ≥4\n10. Patients with multiple lesions requiring both surgery and ablation who cannot represent a single treatment strategy within the study\n\nSurgical Resection Group Inclusion Criteria\n\n1. Adults aged ≥18 years\n2. Histologically or cytologically confirmed stage IA NSCLC (T1N0M0, tumor ≤3 cm)\n3. Determined by multidisciplinary evaluation to have surgical resection as the preferred standard treatment option, and patient agrees to surgical resection.\n4. Tumour size between 2.5 and 3.0 cm, or smaller lesions for which surgery is considered the more appropriate option based on tumour features or safety concerns.\n5. Tumour located in the central third of the lung, or in proximity to heat-sensitive structures where surgery offers better oncologic and safety margins.\n6. Imaging findings suggest possible lymph node involvement or a clinical indication for systematic nodal dissection and pathological staging.\n7. Rapidly growing or high-SUV lesions on PET-CT requiring complete resection and full histologic staging.\n8. Medically fit for general anaesthesia and surgical resection, with capability for intraoperative frozen-section margin assessment\n\nExclusion Criteria\n\n1. Presence of lymph node involvement (N1 or higher) or distant metastases (M1)\n2. High surgical risk or limited pulmonary reserve where a lung-preserving strategy is preferred.\n3. Tumours clearly suitable for ablation (≤2.5 cm, located in the middle or peripheral third, and safely ablatable with adequate margins).\n4. Active pulmonary infection, uncorrectable coagulopathy, or unfit for general anaesthesia or lung resection.\n5. Patients with multiple lesions, some requiring surgery and others ablation, who cannot be assigned to a single treatment strategy within the study.\n6. Pregnant or breastfeeding women\n7. Inability or unwillingness to comply with study procedures",{"count":343,"type":23},292,[345],"PHASE2","This study aims to address the core deficiencies in the field by situating bronchoscopic ablation within the same evidentiary frame as segmentectomy and lobectomy. It will deliver adjusted retrospective comparisons with external validation using population data, a prospective noninferiority evaluation on disease control and safety, quantitative evidence on pulmonary function and quality of life, and translational endpoints linking circulating tumour DNA (ctDNA) dynamics and immune activation to durability of control. The work is directly aligned with Hong Kong service needs, where a safe lung preserving option that shortens recovery and optimises resource use could relieve surgical waiting pressure while maintaining oncologic outcomes.",[348],"Stage IA NSCLC",[350,351,352,348,353],"Bronchoscopic ablation","Robotic assisted bronchoscopy","Image guided ENB","disease-free survival","2026-07-28",{"date":224,"type":36},{"date":247,"type":23},{"date":358,"type":23},"2029-12-31",{"name":42,"class":43},{"id":361,"slug":362,"hasResults":12,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":367,"enrollmentInfo":368,"targetDuration":4,"studyType":24,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":374,"startDateStruct":375,"completionDateStruct":377,"leadSponsor":379,"locationsCount":4},"100569912","phase-2-rct-for-the-chinese-medicine-in-treating-hypercholesterolemia-100569912","NCT06700408","RCT for the Chinese Medicine in Treating Hypercholesterolemia","Efficacy and Safety of Dachaihu Decoction Combined Erzhiwan With Variation for the Treatment of Hypercholesterolemia: A Parallel, Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Age 18-80 years old, any gender;\n* LDL-C level of 4.1 mmol\u002FL or above (no statin therapy during the screening period);\n* Be able to maintain a more consistent lifestyle and eating habits throughout the study;\n* Have a fixed residence and are not expected to move or travel for 8 weeks;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Taking drugs that may affect lipid metabolism (such as steroids, sleeping pills, and psychotropic drugs);\n* Alcohol or drug abuse within the last 3 months;\n* Known liver function or renal dysfunction;\n* History of severe cardiovascular and cerebrovascular diseases; or history of psychiatric illness;\n* Participate in other interventional clinical trials within 3 months before the study, including drugs, supplements, medical devices, etc.;\n* Known pregnant or lactating women, allergies or allergies to traditional Chinese medicine;\n* Patients with known secondary hypercholesterolemia.","80 Years",{"count":369,"type":23},70,[345],"This is a randomized, double-blind, placebo-controlled clinical trial. Eligible subjects will randomized into a treatment group or placebo group. They will receive either Chinese medicine granules or placebo granules for 8 weeks followed by a 4-week observation period. The primary outcome would be the percent change in Low-density lipoprotein cholesterol levels (LDL-C) after treatment.",[373],"Hypercholesterolemia",{"date":330,"type":36},{"date":376,"type":23},"2027-01",{"date":378,"type":23},"2030-04",{"name":42,"class":43},{"id":381,"slug":382,"hasResults":12,"nctId":383,"briefTitle":384,"officialTitle":385,"acronym":4,"eligibilityCriteria":386,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":387,"enrollmentInfo":388,"targetDuration":4,"studyType":24,"phases":390,"briefSummary":391,"conditions":392,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":394,"startDateStruct":395,"completionDateStruct":397,"leadSponsor":399,"locationsCount":44},"100501941","phase-2-shuiniujiao-dihuang-decoction-with-variation-for-the-treatment-of-psoriasis-100501941","NCT05815797","Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis","The Safety and Effects of Using Shuiniujiao Dihuang Decoction With Variation for the Treatment of Psoriasis: A Double-blind, Randomized, Placebo-Controlled Trial","Inclusion Criteria:\n\n* Mild to moderate chronic plaque psoriasis (PASI score 3 to 12).\n* Willingness to give informed consent.\n\nExclusion Criteria:\n\n* Pustular or generalized erythrodermic psoriasis.\n* Psoriatic arthritis with syndrome of spleen-kidney yang deficiency according to Chinese medicine theory.\n* Systemic therapy for psoriasis 6 months prior to baseline.\n* Use topical medications for psoriasis 14 days prior to baseline such as retinoids, corticosteroids, vitamin D analogues, tazarotene and tacrolimus.\n* Has taken any antibiotics, probiotics and prebiotics 30 days prior to baseline.\n* UV light therapy 30 days prior to baseline.\n* Clinically significant laboratory abnormality in blood, liver or renal functions (≥1.5 times the upper limit of reference range).\n* History of allergy to Chinese herbs.\n* Known pregnant or lactation, or have a plan to conceive in 6 months.\n* Known active gastric or duodenal ulcer, or severe arrhythmia.\n* Unwillingness to comply with study protocol.\n* Any other condition that in the opinion of the investigators could disadvantage the subject.","75 Years",{"count":389,"type":23},58,[345],"Psoriasis is an inflammatory skin disease with huge negative impact on the quality of life of the patients, and has an overall prevalence of 2% to 3% in the general population. Plaques psoriasis is the most common type of the disease and presents red, well demarcated, and silvery plaques mainly localized in the umbilical and lumbosacral area as well as in the elbows, knees, and scalp.\n\nCurrently, pharmacological treatments such as retinoids, corticosteroids, vitamin D analogs and biologics remain the main options for most psoriasis patients. However, side effect and high cost barred many ordinary psoriasis patients from benefiting from the treatments.\n\nA Chinese medicine formula \"Shuiniujiao Dihuang Decoction with Variation (SDD)\" was prescribed by Prof. Lin for many years and observed to be effective in relieving psoriasis patients' clinical manifestations.\n\nIn this study, subjects with psoriasis will be randomized into treatment group of \"SDD\" or placebo group for 12 weeks.",[393],"Psoriasis Vulgaris",{"date":330,"type":36},{"date":396,"type":36},"2024-06-11",{"date":398,"type":23},"2027-10",{"name":42,"class":43},{"id":401,"slug":402,"hasResults":12,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":407,"enrollmentInfo":408,"targetDuration":4,"studyType":24,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":44},"100499751","phase-2-rct-for-yinqiaosan-maxingganshitang-in-the-treatment-of-covid-19-100499751","NCT05787327","RCT for Yinqiaosan-Maxingganshitang in the Treatment of COVID-19","Assessing the Efficacy and Safety of Yinqiaosan-Maxingganshitang in the Treatment of the Major Symptoms of Mild and Moderate COVID-19 by Telemedicine - a Randomized, Double-blind, Placebo-controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 65 years;\n* Tested positive for COVID-19 by RATs, Deep Throat Saliva (DTS) or Throat\u002FNasal swab RT-PCR tests;\n* Patient diagnosed with mild to moderate COVID-19 based on the \"Coronavirus disease 2019 (COVID-19) Treatment Guidelines\" published by National Institutes of Health;\n* Duration of symptoms ≤ 72 hours (Start from the presence of the major symptoms of COVID-19: Fever: oral temperature \\>37.2°C, or cough score ≥2, or fatigue score ≥2);\n* Diagnosed with pattern of wind and heat invading the surface and\u002For pattern of intense exuberance of lung heat by a registered Chinese medicine practitioner (CMP) (Diagnostic criteria are the corresponding criteria in the \"Diagnosis standards for common syndromes in traditional Chinese medicine)\" published by \"Diagnostic Subcommittee of China Association of Traditional Chinese Medicine in 2008, with ≥20 as the threshold for determination);\n* Explicit declaration of willingness to participate in the study at the time of videoconference screening after reading the electronic informed consent form (written consent form have to signed after inclusion).\n\nExclusion Criteria:\n\n* Diagnosed of Asymptomatic or Presymptomatic Infection, Severe Illness or Critical Illness of COVID-19 based on the \"Coronavirus disease 2019 (COVID-19) Treatment Guidelines\" published by National Institutes of Health\n* Known allergy to the Chinese medicines or other ingredients of the investigational medicinal products (IMP) used in this study;\n* Known pregnancy or lactation;\n* Known immunocompromised patient (such as malignancy, organ or bone marrow transplant, AIDS or low immune function caused by long-term use of corticosteroids or other immunosuppressants)\n* Known obesity (Body Mass Index \\[BMI\\] ≥30)\n* Heavy smoker (≥400 cigarettes\u002Fyear)\n* Known history of cardiovascular and cerebrovascular diseases (including hypertension), chronic lung disease (chronic obstructive pulmonary disease, moderate and severe asthma or interstitial lung disease), diabetes, chronic liver disease (ALT\u002FAST ≥ 2× the upper limit of normal \\[ULN\\], Bilirubin-Total ≥ 1.5ULN), chronic kidney disease (Creatinine ≥1.5ULN), cancer or other chronic diseases.\n* Known history of dysphagia or any gastrointestinal disorder that affects drug absorption (such as gastroesophageal reflux disease \\[GERD\\], chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, gastrectomy);\n* Suspected or known history of alcohol or substance abuse or mental illness;\n* Subjects having participated in other clinical studies in the past three months;\n* Any other condition that in the opinion of the investigators could compromise the study.","65 Years",{"count":409,"type":23},96,[345],"This is a randomized, double-blinded, placebo-controlled clinical trial. This study is to evaluate the effectiveness and safety of Yinqiaosan-Maxingganshitang in the treatment of the major symptoms of mild and moderate COVID-19 patients by telemedicine.",[413],"COVID-19",{"date":330,"type":36},{"date":416,"type":36},"2023-05-25",{"date":418,"type":23},"2027-09-30",{"name":42,"class":43},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":427,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":44},"100497250","phase-2-yunzhi-essence-to-improve-the-quality-of-life-of-patients-with-advanced-stage-of-cancer-100497250","NCT05754801","Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer","Yunzhi Essence to Improve the Quality of Life of Patients With Advanced Stage of Cancer: A Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Diagnosed with advanced cancer according to the definition from American Cancer Society;\n* According to the experience of the doctor, by using Palliative Prognostic Index (score\\>4), integrated with past cases and professional knowledge judged to have life expectancy not less than six months to two years;\n* Abbreviated mental test (AMT) score of 6 or above;\n* Voluntarily participate in this clinical trial and sign the informed consent form (acceptance of close relatives signed informed consent on behalf of the patient);\n* Refer to the national standard for Clinic terminology of traditional Chinese medical diagnosis and treatment-Part 2:Syndromes\u002Fpatterns, syndrome of \"damp heat spleen\" and \"spleen deficiency with water stop\" (Fulfill 2 of the main symptoms and 2 of the secondary symptoms).\n\nExclusion Criteria:\n\n* Patients with a history of allergy to traditional Chinese medicine or Yunzhi;\n* Patients who required nasal feeding or difficulty swallowing;\n* Patients with comatose\u002Fsemi-conscious, cognitively impaired with dementia\u002Fconfusion, physically too ill with extremely poor general condition, or there was a language barrier.","21 Years","89 Years",{"count":430,"type":23},172,[345],"A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine 'Coriolus Versicolor for improving the quality of life of patients with advanced-stage cancer. Subjects will be randomized into a treatment group or placebo group for 6 months.",[434,435],"Cancer","Palliative Care",{"date":330,"type":36},{"date":438,"type":36},"2024-01-05",{"date":418,"type":23},{"name":42,"class":43},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":454,"startDateStruct":455,"completionDateStruct":457,"leadSponsor":459,"locationsCount":44},"100490411","phase-2-chinese-medicine-for-treating-chronic-pharyngolaryngitis-100490411","NCT05665777","Chinese Medicine for Treating Chronic Pharyngolaryngitis","The Effectiveness and Safety of Qingyan Lihou Decoction for the Treatment of Chronic Pharyngolaryngitis: A Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* 18 years of age or above (Chinese subjects only);\n* Persistent symptoms of pharyngitis (sore throat, globus, dry throat, dry cough, throat irritation) for more than 3 weeks;\n* Determined to be the following Chinese medicine syndromes by Registered Chinese Medicine Practitioners (RCMPs): Wind-heat invading the upper-jiao, or phlegm heat or Yin deficiency;\n* Visual analog scale (VAS) score for pain ≥ 50 mm;\n* Numeric rating scale (NRS) ≥ 6; and\n* Be able to give voluntary written informed consent.\n\nExclusion Criteria:\n\n* Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases;\n* Concomitant use of steroids, nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulants, and immunotherapy within the past week;\n* Impaired hematological profile and liver \u002F renal function exceed the upper limit of the reference value by 2 times;\n* Known Allergic rhinitis;\n* Known Gastroesophageal Reflux Disease (GERD);\n* Known cancer or suspected cancer of throat\u002Foesophagus;\n* Mechanical obstruction of the throat accountable for the symptoms;\n* Known alcohol and\u002For drug abuse;\n* Known allergic history to any Chinese herbal medicines; and\n* Subjects who are known pregnant or lactating.",{"count":449,"type":23},74,[345],"A randomized, double-blinded, placebo-controlled clinical trial using a Chinese Medicine formula in treating Chronic pharyngolaryngitis. Subjects will be randomized into a treatment group or placebo group for 8 weeks, and then followed by an 8-week post-treatment visit.",[453],"Chronic Pharyngolaryngitis (Disorder)",{"date":330,"type":36},{"date":456,"type":36},"2023-03-30",{"date":458,"type":23},"2027-07-31",{"name":42,"class":43},{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":465,"acronym":4,"eligibilityCriteria":466,"healthyVolunteers":12,"sex":18,"minAge":467,"maxAge":367,"enrollmentInfo":468,"targetDuration":4,"studyType":24,"phases":470,"briefSummary":471,"conditions":472,"keywords":474,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":44},"100477919","phase-2-colchicine-use-in-intracranial-atherosclerotic-disease-100477919","NCT05503225","Colchicine Use in Intracranial Atherosclerotic Disease","Colchicine Use in Intracranial Atherosclerotic Disease - a Pilot Open-labelled Randomized Trial","Inclusion Criteria\n\n1. Chinese patients aged 40-80 years old\n2. Patients with symptomatic ICAD of ≥ 50% stenosis in middle cerebral arteries, basilar artery. Degree of stenosis will be quantified by computer tomographic angiography (CTA), magnetic resonance imaging (MRI) or digital subtraction angiography (DSA) by the WASID method (13). Symptomatic ICAD is defined as ischemic stroke or transient ischemic attack with clinical or radiological signs correspond to the vascular territory supplied by the disease vessel.\n3. Patients with first-ever ischaemic stroke within 8 weeks of recruitment\n\nExclusion Criteria\n\n1. Patients who are unable to provide an informed consent\n2. Patients who are contraindicated to contrast MRI scans, e.g. non-MRI compatible pacemaker, claustrophobia, known gadolinium-based contrast allergy, estimated glomerular filtration rate \\\u003C 30mL\u002Fmin\u002F1.73m2, etc.\n3. Patients who have absolute or relative contraindications to colchicine therapy, e.g. colchicine allergy, neuromuscular disorders, haematological diseases, chronic diarrhea, estimated glomerular filtration rate \\\u003C 30mL\u002Fmin\u002F1.73m2, chronic liver disease, etc.\n4. Patients with intracranial stenosis not due to atherosclerosis, e.g. vasculitis, vasospasm, Moyamoya disease, etc.\n5. Pregnancy\n6. Patients with elevated creatine kinase level at randomisation stage of study.\n7. Recurrent gouty arthritis that requires colchicine for \\> 3 months per year;\n8. Inflammatory bowel disease or chronic diarrhea;\n9. Neuromuscular disease or a nontransient creatine kinase level that was greater than three times the upper limit of the normal range (unless due to infarction) for \\> 3 months;\n10. Clinically significant nontransient hematologic abnormalities with hemoglobin \\\u003C10g\u002FdL, white blood cell \\\u003C 4x10\\^9, or platelet \\\u003C 100x10\\^9\u002FL for \\> 3 months;\n11. Alcoholism;\n12. Long term systemic glucocorticoid therapy","40 Years",{"count":469,"type":23},72,[345],"Intracranial atherosclerotic disease (ICAD) is a major ischaemic stroke aetiology in Asia. Influenced by genetics, lifestyle and metabolic risk factors. From the SAMMPRIS cohort, 1-year stroke recurrence risk was 13% even with intensive medical therapy.\n\nIn this pilot randomized, double-blind, placebo-controlled trial, the investigators shall recruit 44 patients with recent ischaemic stroke due to intracranial atherosclerosis (ICAD) with ≥ 50% stenosis. Patients will be randomly assigned to either low-dose colchicine (0.5mg daily) (n=22) or placebo (n=22) for 12 months. High-resolution magnetic resonance vessel wall imaging will be performed at baseline and 12 months. The primary endpoint is a composite of regression of intracranial stenosis, plaque volume, or occurrence of any major adverse cardio- or cerebrovascular events at 12 months. The investigators shall also evaluate safety endpoints including diarrhea, marrow suppression, infections, neuromuscular dysfunction.\n\nNo studies had focused on the use of colchicine in patients with ICAD, which is highly prevalent in Asia. Results from this pilot trial will provide an important basis for a larger-scale main trial in the future.",[473],"ICAD - Intracranial Atherosclerotic Disease",[475,476,477],"ICAD","CVA","colchicine",{"date":330,"type":36},{"date":480,"type":36},"2022-11-28",{"date":482,"type":23},"2028-05-31",{"name":42,"class":43},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":367,"enrollmentInfo":492,"targetDuration":4,"studyType":171,"phases":4,"briefSummary":494,"conditions":495,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":503,"startDateStruct":504,"completionDateStruct":506,"leadSponsor":507,"locationsCount":44},"100468304","doac-in-chinese-patients-with-atrial-fibrillation-100468304","NCT05378035","DOAC in Chinese Patients With Atrial Fibrillation","Direct Oral Anticoagulant Levels in Chinese Patients With Atrial Fibrillation - A Real- World Pharmacokinetic Study","DOAC-REAL","Inclusion Criteria:\n\n* Chinese nonvalvular atrial fibrillation (NVAF) patients on apixaban, dabigatran, edoxaban, or rivaroxaban for 6 months or more.\n* Patients aged 18-80 years old.\n* Patients who are able to provide an informed consent.\n* Patients who are indicated for elective medical procedures that require interruption of direct oral anticoagulants (DOAC) for 48 hours.\n\nExclusion Criteria:\n\n* Patients who developed thromboembolism (e.g. ischemic stroke, ischemic bowel, etc.) or major systemic bleeding (e.g. intracerebral haemorrhage, gastrointestinal bleeding) during DOAC usage.\n* Patients with creatinine clearance by Cockroft-Gault formula ≤ 30 mL\u002Fmin.\n* Patients with inappropriate DOAC dosages with respect to age, body weight, and creatinine clearance.\n* Patients who receive DOAC with indications other than NVAF, such as history of mitral stenosis, metallic heart valve, thrombophilia, venous thromboembolism, etc.\n* Patients with conditions that alter haemostasis besides DOAC use, such as essential thrombocytosis, hepatic congestion, hepatic failure with coagulopathy, etc.",{"count":493,"type":23},427,"Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF). All four DOACs - apixaban, dabigatran, edoxaban, and rivaroxaban - were shown to reduce the risk of major bleeding compared to warfarin. The predictable pharmacokinetic profiles of DOACs also favour their use over warfarin. Together with increasing AF incidence due to population ageing, increased AF detection, and territory-wide reimbursement schemes, DOAC prescriptions have been surging worldwide. In Hong Kong, more than 78,354 patients received DOAC from January 2009 through April 2021 according to the Hospital Authority registry.\n\nThe more liberal use of DOACs has led to new issues that require a thorough understanding of ethnic-specific DOAC pharmacokinetic profiles. For instance, 12- 15% of anticoagulated patients annually required interventional procedures that involve temporary discontinuation of DOAC for 48 hours or more. Although guideline-based periprocedural DOAC interruption resulted in a low 30-day thromboembolism rate of 0.16% - 0.6% in a Caucasian cohort, same measures for elective colonoscopies in a local population-based study resulted in a 30-day periprocedural thromboembolism rate of up to 2.2%. Although these studies cannot be compared directly, the remarkable interethnic discrepancy between the two cohorts warrants further pharmacokinetic and pharmacogenomic studies. More importantly, quantifying residual DOAC levels during the interruption periods may imply on duration of periprocedural DOAC interruption, length of hospital-stay, and the risk of thromboembolic and bleeding complications.\n\nMapping inter- and intra-individual variations in DOAC levels may also impact on the management of ischemic stroke among DOAC recipients. Epidemiological studies have shown alarmingly up to 13% of acute ischemic stroke patients were on anticoagulation prior to stroke onset with increasing number of DOAC. These patients received low rates of recanalization therapy due to apprehension of bleeding complications, thus compromised survival and neurological recovery. A prospective study that reveals Asian-specific DOAC pharmacokinetic profiles may inform cross-disciplinary, territory-wide periprocedural care and acute stroke intervention strategy for the rapidly expanding DOAC population.",[496,497,498,499,500,501,502],"Atrial Fibrillation","Stroke","Stroke, Acute","Brain Diseases","Major Adverse Cardiovascular Event","Arterial Thromboembolism","Venous Thromboembolism",{"date":330,"type":36},{"date":505,"type":36},"2022-09-28",{"date":252,"type":23},{"name":42,"class":43},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":12,"sex":18,"minAge":515,"maxAge":516,"enrollmentInfo":517,"targetDuration":4,"studyType":24,"phases":519,"briefSummary":521,"conditions":522,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":44},"100394708","phase-2-evaluate-the-efficacy-of-using-modified-qing-ying-decoction-in-atopic-dermatitis-children-100394708","NCT04419584","Evaluate the Efficacy of Using Modified Qing-Ying Decoction in Atopic Dermatitis Children","A Randomized Placebo-Controlled Clinical Trial of an Innovative Herbal Formula for Atopic Dermatitis in Children: Evaluations of Modified Qing-Ying Decoction on Efficacy and Gut Microbiome","Inclusion Criteria:\n\n1. Age of 4 to 17 (Chinese only);\n2. With EASI ≥ 10;\n3. Subacute and chronic atopic dermatitis presenting with dry, scaly, erythematous papules and plaques; and\n4. Provide written informed consent form (signed by one of their parents)\n\nExclusion Criteria:\n\n1. History of allergy to Chinese medicines;\n2. AD with Yang deficiency in syndrome differentiation, such as pale looking, always feeling cold, fatigue, chronic diarrhea with loose stool, urinary disorders such as urinary difficulty, excessive urination or incontinence\n3. Known overt bacterial infections in the skin;\n4. Known pregnancy;\n5. Known severe medical conditions, such as cardiovascular, liver or renal dysfunction or Diabetes Mellitus;\n6. Having used oral corticosteroids, oral antibiotics, other immunosuppressive or any preparation of oral herbal medicines for the treatment of AD in the past month;\n7. Having been diagnosed with scabies, allergic contact dermatitis, seborrheic dermatitis or psoriasis; and\n8. Has taken anti-coagulant or anti-platelet drugs in the past month.\n9. Has taken any probiotics, prebiotics in the last month\n10. Known history of glucose-6-phosphate dehydrogenase (G6PD) deficiency","4 Years","17 Years",{"count":518,"type":23},64,[345,520],"PHASE3","The study aims to evaluate the clinical efficacy and safety of the modified Qing-Ying Decoction (mQYD) for the treatment of subacute and chronic atopic dermatitis (AD) in children when compared to the placebo control through examining the clinical symptoms, quality of life, gut microbiome, and Chinese medicine body constitution.\n\nThis is a parallel, randomized, placebo-controlled, double-blind clinical trial. Eligible subjects will be randomly allocated to receive oral mQYD granules or it's placebo granules. Subjects will have 12-week of treatment, and then a 4-week follow-up.",[523],"Atopic Dermatitis",{"date":330,"type":36},{"date":526,"type":36},"2020-09-10",{"date":528,"type":23},"2027-08",{"name":42,"class":43},{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":24,"phases":540,"briefSummary":541,"conditions":542,"keywords":544,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":44},"100562811","phase-2-study-of-yupingfeng-powder-treating-allergic-rhinitis-ar-100562811","NCT06608017","Study of Yupingfeng Powder Treating Allergic Rhinitis (AR)","The Effects of Using Yupingfeng Powder With Variation for the Treatment of Allergic Rhinitis (AR): a Randomized Controlled Trial","RCMARb","Inclusion Criteria:\n\n* Aged 18 or above;\n* Subjects with deficiency of lung and spleen Qi;\n* At least 2 or more allergic symptoms (rhinorrhea, sneezing, nasal obstruction and nasal itching) for a cumulative period greater than 1 hour per day;\n* Understand Chinese;\n* Voluntary written consent.\n\nExclusion Criteria:\n\n* Known chronic disease such as asthma, rhinosinusitis, nasal polyposis;\n* Known severe medical conditions, such as cardiovascular, liver or renal dysfunction, diabetes mellitus, cancers, cerebrovascular diseases, blood system diseases;\n* Concomitant steroid, nonsteroidal anti-inflammatory drugs (NSAIDs), anticoagulant, and immunotherapy within past month;\n* Impaired hematological profile and liver \u002F renal function exceeds the upper limit of the reference value by 2 times ;\n* Known alcohol and \u002F or drug abuse;\n* Known allergic history to any Chinese herbal medicines;\n* Known pregnant or lactating.",{"count":539,"type":23},140,[345,520],"Rhinitis is broadly defined as inflammation of the nasal mucosa. It is a common disorder that affects up to 40% of the population. Allergic rhinitis (AR) is the most common type of chronic rhinitis, affecting 10-20% of the population, and evidence suggests that the prevalence of the disorder is increasing. AR is a very common clinical disease that can occur at any age. Severe allergic rhinitis has been associated with significant impairments in quality of life, sleep and work performance.\n\nNowadays, the main treatment for allergic rhinitis is the use of western medicine, such as steroids and antihistamines. However, many clinical studies have found that the curative effect of western medicine is often not ideal.\n\nFrom the perspective of Chinese medicine, this disease is resulted from the deficiency of Qi and Yang Qi in the lungs, spleen and kidneys. Therefore, according to Chinese medicine theory, tonifying lung and spleen qi is the treatment principle for AR patients. Among different Chinese herbal formulae for AR, Yupingfeng Powder is commonly used for allergic diseases and in AR patients, due to its warm nature and able to improve the functions of the lungs and spleen. Yupingfeng Powder can improve symptoms and quality of life, as well as decrease the levels of interleukin and IgE in AR patients. This study will use Yupingfeng Powder with variation to evaluate its effectiveness and safety in treating AR. Hence, a double-blind, randomized, placebo-controlled clinical trial design with strong scientific rigor will be employed in this study, and it would be able to provide robust clinical evidence on the efficacy and safety of Yupingfeng Powder with variation for AR.\n\nRecruited subjects will be randomly assigned to receive orally Yupingfeng Powder with variation or placebo twice a day for 8 weeks, with follow-up for another 8 weeks after stopping the treatment to observe the duration of efficacy.\n\nIn our previous study, it is shown that Yupingfeng Powder can significantly improve the symptoms of AR, and there was no serious adverse event reported by the subjects. And in this project, we modify the design of the trial to further investigate the efficacy of Yupingfeng Powder with variation for AR patients with a larger sample size.",[543],"Allergic Rhinitis",[545,546,547,548],"allergic rhinitis","Chinese Medicine","Yupingfeng Powder","TCM","2026-07-24",{"date":551,"type":36},"2026-07-27",{"date":553,"type":36},"2025-03-27",{"date":555,"type":23},"2026-12-31",{"name":42,"class":43},{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":407,"enrollmentInfo":564,"targetDuration":4,"studyType":24,"phases":566,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":111,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":574,"locationsCount":44},"100555355","phase-2-chinese-medicine-in-treating-insomnia-100555355","NCT06511011","Chinese Medicine in Treating Insomnia","Efficacy and Safety of Modified Suan ZaoRen Tang-TianWang BuXin Dan in the Treatment of Chronic Insomnia: A Randomized, Double-blinded, Placebo-controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 65 years;\n* Eligible for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, criteria for insomnia disorder. The criteria include having difficulties in falling asleep, difficulties in staying asleep, or early morning awakening with clinically significant consequences for daily life for at least 3 nights per week for at least 6 months;\n* Insomnia Severity Index (ISI) total score of at least 8 indicating insomnia at the clinical level;\n* Diagnosed to be Yin deficiency-induced internal heat pattern according to traditional Chinese Medicine (TCM) theory;\n* Able to complete questionnaires and take medications as scheduled; and\n* Voluntary written consent.\n\nExclusion Criteria:\n\n* Known nervous system disease (eg, stroke, Parkinson's Disease);\n* Known mental disorders (eg, depression or anxiety) or HADS score 11 or above in any either item;\n* Known sleeping related diseases (eg. sleep apnea, nocturnal myoclonus, restless legs, severe nocturnal enuresis or narcolepsy) that may affect the sleeping quality;\n* Known pharmacologically induced insomnia;\n* With symptoms that significantly disturb sleep such as pain, fever, diarrhea, frequent micturition, and cough;\n* Know treatment to comorbid sleep disorders, such as sleep apnea or narcolepsy;\n* Work on shift or on night shift;\n* Concomitant pharmacological treatment or herbal medicines for insomnia within the past month;\n* Known severe medical conditions, such as cardiovascular, liver, kidney or hematopoietic system disease, diabetes mellitus, cancers, cerebrovascular diseases;\n* Impaired hematological profile and liver \u002F renal function exceeds the upper limit of the reference value by 2 times;\n* Known alcohol and \u002F or drug abuse;\n* Known allergic history to any Chinese herbal medicines;\n* Diagnosed to be deficiency of spleen according to TCM theory;\n* Any contraindications for taking Chinese medicines in the opinion of the investigators;\n* Know pregnant or lactating; and\n* Involved in other interventional clinical studies at the same time.",{"count":565,"type":23},76,[345],"This is a randomized, double-blinded, placebo-controlled clinical trial. Eligible participants will randomized into either treatment group (CM granules) or placebo group (placebo granules) for 6 weeks, followed by a post-treatment visit at week 9. The primary outcome is the change in Pittsburgh Sleep Quality Index (PSQI) at week 6.",[569],"Insomnia Chronic",{"date":551,"type":36},{"date":572,"type":36},"2025-09-25",{"date":528,"type":23},{"name":42,"class":43},""]